Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Second malignancies after SCT for Hypodiploid ALL: TP53 mutation

Leucémie Aiguë Lymphoblastique (LAL)

Paediatric Diseases Working Party (PDWP)

Type de traitement

Investigateur principal

Laura Bettini (Monza)

ALL study, patients transplanted between 2 and 4 years old

Études rétrospectives

Leucémie Aiguë Lymphoblastique (LAL)

Paediatric Diseases Working Party (PDWP)

Type de traitement

Investigateur principal

Krzysztof Kalwak

Use of Letermovir after transplant in pediatric patients

Études rétrospectives

Toutes les maladies

Paediatric Diseases Working Party (PDWP)

Type de traitement

Investigateur principal

Giovanna Lucchini (London)

Impact of Donor and Patient CMV Serology for malignant

Études rétrospectives

Leucémie Myéloïde Aiguë (LMA)

Leucémie Aiguë Lymphoblastique (LAL)

Leucémie Lymphoïde Chronique (LLC)

Autres tumeurs malignes myéloïdes ou lymphoïdes

Paediatric Diseases Working Party (PDWP)

Type de traitement

Investigateur principal

Elif Ince (Ankara)

Impact of the acute GVH on outcomes in ALL

Études rétrospectives

Leucémie Aiguë Lymphoblastique (LAL)

Paediatric Diseases Working Party (PDWP)

Type de traitement

Investigateur principal

Giovanna Lucchini (London)

Evaluating the Impact of ABO Compatibility on Allogeneic Stem Cell Transplantation Outcomes

Études rétrospectives

Toutes les maladies

Transplant Complications Working Party (TCWP)

Type de traitement

Investigateur principal

Survey on the use of DLI after allogeneic after allogeneic stem cell transplantation across EBMT centers

Toutes les maladies

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Injection de lymphocyte de donneur (DLI)

Investigateur principal

Outcome of transplant in PNH patients treated after 2011

Études rétrospectives

Aplasie Médullaire

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Investigateur principal

Transplant outcomes in patients over 40 years old with severe aplastic anemia (SAA) treated after 2010

Retrospective Studies

Bone marrow failure

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Investigateur principal

Antonio Risitano

Résultats de la greffe chez les patients atteints d'aplasie médullaire sévère (SAA) âgés de plus de 40 ans et traités après 2010

Études rétrospectives

Aplasie Médullaire

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Investigateur principal

Antonio Risitano

Allogeneic Hematopoietic Stem Cell Transplantation for ERCC6L2 disease

Aplasie Médullaire

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Investigateur principal

Ulla Wartiovaara-Kautto, Outi Kilpivaara and Flore Sicre de Fontbrune

Allogeneic HSCT in ICU setting

Aplasie Médullaire

Severe Aplastic Anaemia Working Party (SAAWP)

Type de traitement

Investigateur principal

Tayfun Güngör